Zurcher Kantonalbank Zurich Cantonalbank Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 139,749 shares of the biopharmaceutical company’s stock after selling 5,116 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Regeneron Pharmaceuticals were worth $146,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Rakuten Securities Inc. raised its position in Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares during the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $26,000. Sachetta LLC lifted its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on REGN. BMO Capital Markets cut their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Citigroup started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price on the stock. Finally, Barclays decreased their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $754.87 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The company’s 50 day simple moving average is $921.45 and its 200 day simple moving average is $1,022.55. The company has a market capitalization of $82.95 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.89 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.